A Wetherby-based company says that increased sales of its living skin equivalent are helping to reduce animal testing.
Evocutis has secured sales with leading cosmetic and pharmaceutical companies of its trademarked LabSkin product, which also provides an alternative to live human skin testing.
The sales are included in contracts worth £280,000 with well-known consumer healthcare and pharmaceutical companies in the US and Europe.
Gwyn Humphreys, chief executive officer of Evocutis, said: “We have seen a positive response to LabSkin from the pharmaceutical and cosmetics markets, demonstrating the need for ethical and cost-effective alternatives to tests on living skin in leading laboratories.”
LabSkin is used in product development and to support claims used in marketing. Because it acts much like human skin, it offers an alternative to ethically sensitive and expensive animal and human volunteer testing.
A collaboration with the University of Bradford’s Centre for Skin Sciences could see it adapted for different skin types and colours, helping to improve the testing of sunscreen products.